Re-Vana Therapeutics is an ocular pharmaceutical​ and drug delivery company focused on the development and commercialisation of revolutionary long-acting biodegradable drug delivery platforms to treat chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma and ocular infections.


Pharmaceutical

Re-Vana Therapeutics

Michael O’rourke

Gregoire Schwach

Wenrui Zhang

Sandip Gite

Shivanki Sahay

Peter McKenna

Jenna Hewitt

Lucy Finlay

Ravi Deevi

Sangdi Wang

Patrick H O’ruane

Tom Biancardi

Thakur Raghu Raj Singh

David Waite

The executive team at Re-Vana Therapeutics has a long history in the pharmaceutics industry and academia. The team includes a Reader in Pharmaceutics, Chair of the Ocular Delivery Focus Group, and Senior Lecturer and Lecturer in Pharmaceutics, all from Queen's University Belfast. They also hold degrees in Drug Delivery and Higher Education/Higher Education Administration from Queens University Belfast.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at Re-Vana Therapeutics

Board of Directors

Leadership Team